Skip to main content

Heft Nr. 12/2024

Heft Nr. 12/2024

Anzeigenschluss: 19.11.2024 
Erscheinungstermin: 12.12.2024

Download als PDF

Schwerpunkt: Liquid Biopsy

Editorial
G. Schuch
Beitrag 1

M. Janning
Liquid Biopsy beim NSCLC

Beitrag 2
K. Clemm von Hohenburg
Liquid Biopsy in der Hämatologie

Beitrag 3
N.N.
Liquid Biopsy in der HNO

Journal Club
Brustkrebs
Bardia et al.
TROPION-Breast01: Datopotamab deruxtecan vs chemotherapy in pre-treated inoperable or metastatic HR+/HER2– breast cancer (+ Kommentar von  Andreas Schalhorn)

Endometrium-Karzinom
Colombo et al.
Atezolizumab and chemotherapy for advanced or recurrent endometrial cancer (AtTEnd): a randomised, double-blind, placebo-controlled, phase 3 trial (+ Kommentar von Michael Eichbaum)

Hepatozelluläres Karzinom
Rodriguez et al.
Hepatocellular carcinoma in metabolic dysfunction-associated steatotic liver disease

NSCLC
Lu et al.
Osimertinib after Chemoradiotherapy in Stage III EGFR-Mutated NSCLC

Melanoma
Wolchok et al.
Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma (+ Kommentar von  Andreas Schalhorn)

Neues aus der Forschung
Leukämie
Tix et al.
Second primary malignancies after CAR T-cell therapy: A systematic review and meta-analysis of 5,517 lymphoma and myeloma patients.

Brustkrebs
Kiser et al.
Screening Familial Risk for Hereditary Breast and Ovarian Cancer.

NSCLC
Han et al.
Plinabulin plus docetaxel versus docetaxel in patients with non-small-cell lung cancer after disease progression on platinum-based regimen (DUBLIN-3): a phase 3, international, multicentre, single-blind, parallel group, randomised controlled trial.

Leberzellkarzinom
Dawson et al.
Palliative radiotherapy versus best supportive care in patients with painful hepatic cancer (CCTG HE1): a multicentre, open-label, randomised, controlled, phase 3 study

CME-Fortbildung
Leberzellkarzinom
A. Kobe
Leberzellkarzinom

Onkologie aktuell
Lymphome
Kongressbericht: ISHL (International Symposium on Hodgkin Lymphoma)

Allgemeine Onkologie
Kongressbericht: ESMO-Kongress


*Die Redaktion behält sich aktuelle Änderungen vor.